- Stocks of Vitalhub have grown nearly 73 per cent year-to-date (YTD). Its scrip’s present price-to-cashflow stands at 182.40.
- Units of Hamilton have returned over 33 per cent YTD. The stock offers a positive return on equity of 2.22 per cent.
- Both penny stocks have been ranked among TMX’s top healthcare and junior healthcare companies.
Canadian healthcare companies have been focused on advancing research and development (R&D) across medicine, vaccines, and therapies to deal with the COVID-19 crisis. Going forward, every sector will have to collaborate with healthcare companies to safeguard their employees and customers.
Drug manufactures have been using high-end technology to accelerate their research across the globe. In the wake of the R&D transition, let us look at the following two penny healthcare stocks:
Vitalhub Corp. (TSXV: VHI)
Toronto-based Vitalhub Corp builds technology solutions for health and mental health-related services providers.
Stocks of the healthcare company have rallied by nearly 73 per cent year-to-date (YTD). The unit has surged almost 27 per cent in the last three months. Thus, its scrip made it to TMX’s top healthcare stocks that have surpassed their peers with the largest price gain in the last one month. The company also ranks highly among junior health companies.
The unit’s price-to-cashflow ratio is 182.40, and its present price-to-book ratio stands at 2.85. The units have a current market cap of approximately C$ 99.9 million and a debt-to-equity ratio of 0.25 as per the TMX portal.
In the third quarter ended on September 30, 2020, the company reported revenue of C$ 3.192,166 as compared to C$ 2,395,662, an increase of 33.2 per cent. The company acquired Intouch with Health Ltd. and Transforming Systems Ltd. in the third quarter of 2020.
Hamilton Thorne Ltd. (TSXV: HTL)
The US-based company offers precision instruments, software-driven devices, and services that reduce cost. Stocks of the company have returned over 33 per cent YTD. The stock has marginally gained 3 per cent in the last three months. This health device developer also made it to TMX’s top healthcare and junior healthcare companies.
The stock’s price-to-book ratio is 3.14, and its price-to-cashflow ratio is 26.30. The stock delivers a positive return on equity of 2.22 per cent and a return on assets of 1.54 per cent. The stock is offering earnings per share of C$ 0.01. Its debt-to-equity ratio stands at 0.24, according to TMX data.
The company has a current market cap of C$ 193.9 million. For the quarter ended on September 2020, the company posted sales of C$ 9.8 million for the quarter, a surge of 10 per cent year-over-year (YoY)